←
Peter Adams🇪🇺🇺🇳1,686 posts
Peter Adams🇪🇺🇺🇳 avatar

Peter Adams🇪🇺🇺🇳

@AdamsBioAging

Director NCI-designated Cancer Genome and Epigenetics Program at SBP, Co-Editor-in-Chief Aging Biology Journal, Road/Gravel/Mtn Cycling, Wolf Pack Cycling.

◷ Joined August 2020▧ 108 Photos and videos
João Pedro de Magalhães avatar
⟳ Peter Adams🇪🇺🇺🇳 retweeted
João Pedro de Magalhães@jpsenescence·Nov 16

Just one week left to apply for the PhD studentship in our lab! Join us at @InflamAge_UoB and work at the intersection of machine learning/AI, ageing and longevity 🚀

Want to do a PhD in ageing and rejuvenation? Join our lab @unibirmingham ! We have a PhD studentship @MIBTP_BBSRC for a project @InflamAge_UoB to study ageing, longevity and cellular rejuvenation. Deadline: 23 November 2026. For more details about the project: findaphd.com/phds/project/de… 1/2

Post attachment
Peter Adams🇪🇺🇺🇳 avatar
Peter Adams🇪🇺🇺🇳@AdamsBioAging·Sep 30

Great study from @ACovarrubiasPhD and team. In our recent paper on Cyclin D1 in senescence pubmed.ncbi.nlm.nih.gov/4262… we noted that Cyclin D2 was up in senescence. Anthony and team have figured out the function. Surprising new roles for both D1 and D2. See also work of @marc_dema

The p53-p21-Cyclin D2 regulatory axis drives metabolic reprogramming and a distinct senescent macrophage senotype during aging and MASLD biorxiv.org/content/10.64898…

Peter Adams🇪🇺🇺🇳 avatar
Peter Adams🇪🇺🇺🇳@AdamsBioAging·Sep 27

Could we have got here earlier if not such a focus on amyloid and tau as targets? ApoE has been telling us for years that cholesterol/lipid metabolism is important in Alzheimer’s

1/ Do you carry ApoE4? About 1 in 4 ppl do. 1 copy: ~3X Alzheimer's risk. 2 copies: ~10X. On Sept 21, Europe approved obicetrapib, a cholesterol drug that, in a large trial, lowered multiple AD markers in ApoE4 carriers. Yes, a drug engineered to prevent heart attacks seems to lower AD biomarkers. Read on for details.

Post attachment
Peter Adams🇪🇺🇺🇳 avatar
Peter Adams🇪🇺🇺🇳@AdamsBioAging·Sep 27

Great thread. This is very exciting, if it holds up and extends to cognition/disease prevention. Obicetrapib is one of the most exciting emerging new drugs.

1/ Do you carry ApoE4? About 1 in 4 ppl do. 1 copy: ~3X Alzheimer's risk. 2 copies: ~10X. On Sept 21, Europe approved obicetrapib, a cholesterol drug that, in a large trial, lowered multiple AD markers in ApoE4 carriers. Yes, a drug engineered to prevent heart attacks seems to lower AD biomarkers. Read on for details.

Post attachment
Peter Adams🇪🇺🇺🇳 avatar
Peter Adams🇪🇺🇺🇳@AdamsBioAging·Sep 18

Agree this is a great synthesis - and I think can likely be applied to other aging disease mechanisms in other tissues; for example, pathology caused by senescent cells, inflammation…….can also apply to interactions between multiple “hallmarks of aging”

A brilliant new @Nature synthesis of what we know about Alzheimer's disease pathogenesis, which is non-linear, with discrete phases (Figure), and notable inflection and transition points. Also helps to explain why symptoms do not correlate with underlying pathology. nature.com/articles/s41586-0…

Post attachment
Aging Science News avatar
⟳ Peter Adams🇪🇺🇺🇳 retweeted
Aging Science News@AgingBiology·Sep 15

Nuclear export of R-loop by the DDX1 and XPO1 complex promotes senescence-associated secretory phenotype and inflammaging nature.com/articles/s43587-0…

Peter Adams🇪🇺🇺🇳 avatar
Peter Adams🇪🇺🇺🇳@AdamsBioAging·Sep 1

Fascinating discussion with Julia Belk and my @sennetresearch colleague Nathan Zemke on age- dependent replacement of brain microglia. Consequences not clear to me though. Nathan et al seem to suggest detrimental, but Julia et al protective from Alzheimer’s. Both, perhaps?

Around age 50 your blood monocytes (Micro 2) begin a "hostile takeover" replacement of your brain microglia immune cells (Micro 1) and can promote inflammation. Two impressive studies made this remarkable discovery independently with different methods. In conversation with their lead authors, @juliabelk and Nathan Zemke erictopol.substack.com/p/two…

Post attachment
Peter Adams🇪🇺🇺🇳 avatar
Peter Adams🇪🇺🇺🇳@AdamsBioAging·Aug 25

A paradoxical role for Cyclin D1 in senescent cells. Unexpected expression of CCND1 in senescent cells was shown decades ago. @AdarshRajesh5 and Boshi Wang (@marc_dema lab) showed pro-inflammatory function. nature.com/articles/s43587-0… nature.com/articles/s43587-0… nature.com/articles/s43587-0…